Guizhou Sanli disclosed the semi -annual report of 2022, realizing revenue of 430 million yuan
Author:Capital state Time:2022.08.26
On August 26, 2022, the A -share listed company Guizhou Sanli (code: 603439.SH) released the 2022 semi -annual performance report.
From January 1, 2022-June 30, 2022, the company realized operating income of 430 million yuan, an increase of 14.01%year-on-year, and net profit was 63.9919 million yuan, a year-on-year decrease of 7.78%, and the basic earnings per share were 0.16 yuan.
The company's industry is Chinese medicine.
During the company's reporting period, the total assets at the end of the period were 1.540 billion yuan, the operating profit was 69.888 million yuan, the accounts receivable were 297 million yuan, and the net cash flow generated by operating activities was 77.357 million yuan.Cash is 488 million yuan.
Guizhou Sanli, the company's full name of Guizhou Sanli Pharmaceutical Co., Ltd., was established on September 22, 1995. Zhang Hai, the current general manager, is the development, production and sales of drugs.
- END -
After the epidemic, the rent is "up"?What should I think of the rental market in the post -epidemic era?
Recently, if you want to ask when you have to attract the most? The rental market ...
Banking Insurance Regulatory Commission: Cooperate with local governments to actively promote the work of "keeping diplomatic relations, protecting people's livelihood, and stable stability"
Liu Zhongrui, the person in charge of the Statistics and Risk Monitoring Department of Zhongxin Jingwei on July 21, mentioned on the 21st that the marketization of financial institutions participated